Abstracts tagged "drug therapy"

Abstract Number: 1909 • 2012 ACR/ARHP Annual Meeting
Use of Uric Lowering Therapies within a Large Health Care System
Robert A. Overman¹, Brian F. Mandell² and Chad L. Deal³, ¹Rheumatology, Cleveland Clinic Foundation, Cleveland, OH, ²Dept of Rheum/Immun NA10, The Cleveland Clinic, Cleveland, OH, ³Dept of Rheum & Imm Dis /A 50, Cleveland Clinic, Cleveland, OH
Background/Purpose: Guidelines for initiating urate lowering therapy (ULT) in the treatment of gout recommend treatment to a target serum urate (SUA) level of ≤6mg/dl with…
Abstract Number: 1895 • 2012 ACR/ARHP Annual Meeting
Safety Competences Knowledge and Behavioural Skills of Patients Treated by Biologics in Rheumatology
Anne-Christine Rat¹, Bruno Fautrel², Elisabeth Flipon³, Laure Gossec⁴, Benoit-Damien Caritey⁵, Laurent Marguerie⁶, Henri Nataf⁷, Beatrice Pallot Prades⁸, Rose Marie Poilvert⁹, Valerie Royant¹⁰, Fathia Sadji¹¹, Christelle Sordet¹², Corinne Thevenot¹³ and Catherine Beauvais¹⁴, ¹CHU Nancy, Clinical Epidemiology and Evaluation, Université de Lorraine, Paris Descartes University, APEMAC, EA 4360, Nancy, France, ²Rheumatology / GRC08-EEMOIS, APHP-Pitie Salpetriere Hospital / UPMC, Paris, France, ³Cochin hospital, Paris, France, ⁴Rheumatology B Department, Paris-Descartes University, Cochin Hospital, Paris, France, ⁵Epidemiology, Université de lorraine, Nancy, France, ⁶Rheumatology department, Institut Calot, Berck, France, ⁷Mantes-la-Jolie, Mantes-la-Jolie, France, ⁸Rheumatology department, Saint Etienne university hospital, Saint Etienne, France, ⁹Rheumatology department, Saint Antoine Hospital, Paris, France, ¹⁰Chartres, Chartres, ¹¹Rheumatology department, Victor Jousselin Hospital, Dreux, France, ¹²Rheumatology, Strasbourg University Hospital, Strasbourg, France, ¹³Department of Internal Medicine, Laon hospital, Laon, France, ¹⁴Rhumatologie, Saint Antoine, Paris, France
Background/Purpose: Biologics are known to entail specific risks; therefore teaching patients safety skills, appropriate behaviours in situations of risks and what decisions to take in…
Abstract Number: 1715 • 2012 ACR/ARHP Annual Meeting
Imatinib Mesylate (Gleevec™) in the Treatment of Diffuse Cutaneous Systemic Sclerosis: Results of a 24 Month Open Label, Extension Phase
Jessica K. Gordon¹, Morgana L. Davids², Kamini Doobay², Jamie N. Mersten¹, Cynthia Magro³, Horatio F. Wildman⁴, Stephen L. Lyman⁵, Mary K. Crow⁶ and Robert F. Spiera¹, ¹Rheumatology, Hospital for Special Surgery, New York, NY, ²Medicine/Rheumatology, Hospital for Special Surgery, New York, NY, ³Dermatopathology, Weill-Cornell Medical Center, New York, NY, ⁴Dermatology, Weill-Cornell Medical Center, New York, NY, ⁵Research, Hospital for Special Surgery, New York, NY, ⁶Department of Medicine, Hospital for Special Surgery, New York, NY
Background/Purpose: Imatinib mesylate (IM) has been shown to decrease fibrosis in preclinical models and is a treatment of interest for Systemic Sclerosis (SSc). We have…
Abstract Number: 1595 • 2012 ACR/ARHP Annual Meeting
Genome-Wide Association Study to High -Throughput Cell-Based Phenotypic Screen Identifies Novel Chemical Inhibitors of CD40 Signaling
Gang Li¹, Dorothee Diogo², Di Wu¹, Jim Spoonamore³, Rheumatoid Arthritis Consortium International (RACI)⁴, Eli Stahl⁵, Nicola Tolliday³ and Robert M. Plenge⁶, ¹Division of Rheumatology, Immunology and Allergy and Division of Genetics, Brigham and Women's Hospital, Boston, MA, ²Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, ³Broad Institute, Cambridge, MA, ⁴Boston, ⁵Brigham and Women's Hospital, ⁶Division of Rheumatology, Immunology and Allergy and Division of Genetics, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Deriving therapeutic targets from human genetics linked with biological alterations of risk alleles may provide a more successful approach to drug development than traditional…
Abstract Number: 1149 • 2012 ACR/ARHP Annual Meeting
Long-Term Safety of Etanercept in Patients with Juvenile Idiopathic Arthritis (JIA)
Kirsten Minden¹, Martina Niewerth², Jens Klotsche³, Michael Hammer⁴, Johannes Peter Haas⁵, Gerd Ganser⁶ and Gerd Horneff⁷, ¹Programme Area Epidemiology, German Rheumatism Research Center, a Leibniz Institute, Berlin, Germany, ²Epidemiology, German Rheumatism Research Centre, Berlin, Germany, ³Programme Area Epidemiology, German Rheumatism Research Center, a Leibniz institute, Berlin, Germany, ⁴Klinik fuer Rheumatologie, St. Josef-Stift, Sendenhorst, Germany, ⁵German Center for Pediatric and Adolescent Rheumatology, Garmisch-Partenkirchen, Germany, ⁶Pediatric Rheumatology, Sankt Josef Stift, Sendenhorst, Germany, ⁷Department of Pediatrics, Centre of Pediatric Rheumatology, Sankt Augustin, Germany
Background/Purpose: Etanercept (Eta) has been the most frequently used biologic drug in patients with JIA. In Germany, about one in three patients with polyarticular JIA…
Abstract Number: 802 • 2012 ACR/ARHP Annual Meeting
Milnacipran Reduces Brain Activity During Pain in Fibromyalgia
Anson E. Kairys¹, Richard E. Harris², Eric Ichesco², Johnson P. Hampson², Steven Harte², Daniel J. Clauw³ and Tobias Schmidt-Wilcke², ¹Department of Anesthesiology, Chronic Pain and Fatigue Research Center, University of Michigan, Ann Arbor, MI, ²Anesthesiology, University of Michigan, Ann Arbor, MI, ³Anesthesiology/Internal Medicine (Rheum), University of Michigan, Ann Arbor, MI
Background/Purpose: Fibromyalgia (FM) is a chronic pain condition characterized by widespread musculoskeletal pain and a number of concomitant symptoms such as fatigue, sleep disturbance, cognitive…
Abstract Number: 805 • 2012 ACR/ARHP Annual Meeting
Milnacipran Increases Cortical to Brainstem Connectivity During Pain in Fibromyalgia
Eric Ichesco¹, Tobias Schmidt-Wilcke¹, Anson E. Kairys², Johnson P. Hampson¹, Steven E. Harte¹, Daniel J. Clauw³ and Richard E. Harris¹, ¹Anesthesiology, University of Michigan, Ann Arbor, MI, ²Department of Anesthesiology, Chronic Pain and Fatigue Research Center, University of Michigan, Ann Arbor, MI, ³Anesthesiology/Internal Medicine (Rheum), University of Michigan, Ann Arbor, MI
Background/Purpose: Fibromyalgia (FM) is a chronic widespread pain disorder characterized by muscle tenderness, fatigue, poor sleep, and mood disturbance. Milnacipran is a dual serotonin-norepinephrine reuptake…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.